Iteos Therapeutics Inc expected to post a loss of $1.06 a share - Earnings Preview

iTeos Therapeutics

05/03/2025 13:32

Iteos Therapeutics Inc ITOS.OQ ITOS.O is expected to show no change in quarterly revenue when it reports  results on March 7 (estimated) for the period ending December 31 2024

‚ÄčLSEG's mean analyst estimate for Iteos Therapeutics Inc is for a loss of $1.06 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Iteos Therapeutics Inc is $21.39‚Äč, above‚Äč its last closing price of $6.85. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.15
-0.89
-1.05
Missed
-18.1
Jun. 30 2024
-1.04
-1.04
-0.18
Beat
82.7
Mar. 31 2024
-0.97
-1.26
-1.07
Beat
14.8‚Äč
Dec. 31 2023
-0.93
-1.03
-0.85
Beat
17.7
‚Äč‚ÄčSep. 30 2023
-1.14
-1.20
-0.90
Beat
25.2
Jun. 30 2023
-0.98
-1.03
-0.96
Beat
6.8‚Äč
Mar. 31 2023
-1.00
-0.99
-0.44
Beat
55.8
Dec. 31 2022
0.33


This summary was machine generated March 5 at 13:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)